C
Neurocrine Biosciences, Inc.
NBIX
$108.31
$1.311.22%
C
Hold
2/11/2025Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 2/11/2025 due to a decline in the valuation index, solvency index and growth index. Debt to equity increased from 0.01 to 0.02, EBIT declined 29.11% from $184.8M to $131M, and the quick ratio declined from 3.98 to 3.06.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 2/11/2025 due to a decline in the valuation index, solvency index and growth index. Debt to equity increased from 0.01 to 0.02, EBIT declined 29.11% from $184.8M to $131M, and the quick ratio declined from 3.98 to 3.06.
B
Buy
2/10/2025Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C+ on 2/10/2025 due to an increase in the total return index, growth index and solvency index. Operating cash flow increased 144.58% from $64.6M to $158M, earnings per share increased from $0.63 to $1.24, and EBIT increased 24.95% from $147.9M to $184.8M.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C+ on 2/10/2025 due to an increase in the total return index, growth index and solvency index. Operating cash flow increased 144.58% from $64.6M to $158M, earnings per share increased from $0.63 to $1.24, and EBIT increased 24.95% from $147.9M to $184.8M.
C
Hold
10/4/2024Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 10/4/2024 due to a decline in the volatility index and total return index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 10/4/2024 due to a decline in the volatility index and total return index.
B
Buy
9/19/2024Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C+ on 9/19/2024 due to an increase in the valuation index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C+ on 9/19/2024 due to an increase in the valuation index.
C
Hold
9/4/2024Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 9/4/2024 due to a decline in the total return index and volatility index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 9/4/2024 due to a decline in the total return index and volatility index.
B
Buy
8/2/2024Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C+ on 8/2/2024 due to a substantial increase in the growth index and solvency index. Debt to equity declined from 0.07 to 0.01, the quick ratio increased from 2.33 to 3.78, and earnings per share increased from $0.42 to $0.63.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C+ on 8/2/2024 due to a substantial increase in the growth index and solvency index. Debt to equity declined from 0.07 to 0.01, the quick ratio increased from 2.33 to 3.78, and earnings per share increased from $0.42 to $0.63.
C
Hold
5/20/2024Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 5/20/2024 due to a large decline in the total return index and valuation index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 5/20/2024 due to a large decline in the total return index and valuation index.
B
Buy
5/3/2024Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C+ on 5/3/2024 due to a large increase in the solvency index, valuation index and volatility index. Debt to equity declined from 0.09 to 0.07, and the quick ratio increased from 2.25 to 2.33.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C+ on 5/3/2024 due to a large increase in the solvency index, valuation index and volatility index. Debt to equity declined from 0.09 to 0.07, and the quick ratio increased from 2.25 to 2.33.
C
Hold
3/28/2024Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 3/28/2024 due to a large increase in the total return index and volatility index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 3/28/2024 due to a large increase in the total return index and volatility index.
C
Hold
3/13/2024Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 3/13/2024 due to a decline in the total return index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 3/13/2024 due to a decline in the total return index.
C
Hold
2/14/2024Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 2/14/2024 due to an increase in the total return index, valuation index and volatility index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 2/14/2024 due to an increase in the total return index, valuation index and volatility index.
C
Hold
12/6/2023Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 12/6/2023 due to a decline in the valuation index and total return index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 12/6/2023 due to a decline in the valuation index and total return index.
C
Hold
11/21/2023Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 11/21/2023 due to a noticeable increase in the volatility index, growth index and total return index. EBIT increased 91.85% from $73.6M to $141.2M, operating cash flow increased 18.04% from $179.6M to $212M, and total revenue increased 10.18% from $452.7M to $498.8M.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 11/21/2023 due to a noticeable increase in the volatility index, growth index and total return index. EBIT increased 91.85% from $73.6M to $141.2M, operating cash flow increased 18.04% from $179.6M to $212M, and total revenue increased 10.18% from $452.7M to $498.8M.
C
Hold
8/2/2023Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from D+ on 8/2/2023 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 243.45% from -$125.2M to $179.6M, net income increased 224.67% from -$76.6M to $95.5M, and earnings per share increased from -$0.79 to $0.95.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from D+ on 8/2/2023 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 243.45% from -$125.2M to $179.6M, net income increased 224.67% from -$76.6M to $95.5M, and earnings per share increased from -$0.79 to $0.95.
D
Sell
5/4/2023Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C on 5/4/2023 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.8772 to -$0.79, operating cash flow declined 187.55% from $143M to -$125.2M, and net income declined 186.07% from $89M to -$76.6M.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C on 5/4/2023 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.8772 to -$0.79, operating cash flow declined 187.55% from $143M to -$125.2M, and net income declined 186.07% from $89M to -$76.6M.
C
Hold
3/3/2023Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 3/3/2023 due to a decline in the volatility index and total return index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 3/3/2023 due to a decline in the volatility index and total return index.
C
Hold
2/10/2023Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 2/10/2023 due to a substantial increase in the growth index, valuation index and efficiency index. Operating cash flow increased 44.74% from $98.8M to $143M, net income increased 29.93% from $68.5M to $89M, and earnings per share increased from $0.69 to $0.8772.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 2/10/2023 due to a substantial increase in the growth index, valuation index and efficiency index. Operating cash flow increased 44.74% from $98.8M to $143M, net income increased 29.93% from $68.5M to $89M, and earnings per share increased from $0.69 to $0.8772.
C
Hold
11/2/2022Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 11/2/2022 due to a significant increase in the growth index, efficiency index and total return index. Net income increased 505.33% from -$16.9M to $68.5M, earnings per share increased from -$0.18 to $0.69, and EBIT increased 60.51% from $54.7M to $87.8M.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 11/2/2022 due to a significant increase in the growth index, efficiency index and total return index. Net income increased 505.33% from -$16.9M to $68.5M, earnings per share increased from -$0.18 to $0.69, and EBIT increased 60.51% from $54.7M to $87.8M.
C
Hold
10/21/2022Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 10/21/2022 due to a noticeable increase in the total return index and volatility index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 10/21/2022 due to a noticeable increase in the total return index and volatility index.
D
Sell
8/8/2022Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C on 8/8/2022 due to a significant decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.14 to -$0.18, net income declined 221.58% from $13.9M to -$16.9M, and total capital declined 9.49% from $1.89B to $1.71B.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C on 8/8/2022 due to a significant decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.14 to -$0.18, net income declined 221.58% from $13.9M to -$16.9M, and total capital declined 9.49% from $1.89B to $1.71B.
C
Hold
6/8/2022Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 6/8/2022 due to an increase in the volatility index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 6/8/2022 due to an increase in the volatility index.
C
Hold
5/5/2022Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 5/5/2022 due to a significant increase in the growth index, total return index and efficiency index. Net income increased 290.41% from -$7.3M to $13.9M, earnings per share increased from -$0.0769 to $0.14, and total capital increased 3.13% from $1.83B to $1.89B.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 5/5/2022 due to a significant increase in the growth index, total return index and efficiency index. Net income increased 290.41% from -$7.3M to $13.9M, earnings per share increased from -$0.0769 to $0.14, and total capital increased 3.13% from $1.83B to $1.89B.
D
Sell
2/11/2022Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C- on 2/11/2022 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.23 to -$0.0769, net income declined 132.44% from $22.5M to -$7.3M, and operating cash flow declined 93.2% from $61.8M to $4.2M.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C- on 2/11/2022 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.23 to -$0.0769, net income declined 132.44% from $22.5M to -$7.3M, and operating cash flow declined 93.2% from $61.8M to $4.2M.
C
Hold
1/7/2022Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C- from C on 1/7/2022 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from $0.43 to $0.23, operating cash flow declined 40.12% from $103.2M to $61.8M, and EBIT declined 34.37% from $67.8M to $44.5M.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C- from C on 1/7/2022 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from $0.43 to $0.23, operating cash flow declined 40.12% from $103.2M to $61.8M, and EBIT declined 34.37% from $67.8M to $44.5M.
C
Hold
3/10/2021Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 3/10/2021 due to a decline in the volatility index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 3/10/2021 due to a decline in the volatility index.
C
Hold
2/16/2021Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 2/16/2021 due to an increase in the total return index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C+ from C on 2/16/2021 due to an increase in the total return index.
C
Hold
2/9/2021Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 2/9/2021 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 703.99% from -$57.6M to $347.9M, earnings per share increased from -$0.62 to $3.5707, and operating cash flow increased 608% from -$17.5M to $88.9M.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 2/9/2021 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 703.99% from -$57.6M to $347.9M, earnings per share increased from -$0.62 to $3.5707, and operating cash flow increased 608% from -$17.5M to $88.9M.
C
Hold
1/4/2021Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 1/4/2021 due to an increase in the total return index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 1/4/2021 due to an increase in the total return index.
D
Sell
12/18/2020Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C- on 12/18/2020 due to a decline in the total return index, volatility index and efficiency index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C- on 12/18/2020 due to a decline in the total return index, volatility index and efficiency index.
C
Hold
11/10/2020Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C- from C on 11/10/2020 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.81 to -$0.62, net income declined 172.36% from $79.6M to -$57.6M, and operating cash flow declined 114.72% from $118.9M to -$17.5M.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C- from C on 11/10/2020 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.81 to -$0.62, net income declined 172.36% from $79.6M to -$57.6M, and operating cash flow declined 114.72% from $118.9M to -$17.5M.
C
Hold
10/16/2020Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 10/16/2020 due to a decline in the total return index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C from C+ on 10/16/2020 due to a decline in the total return index.
C
Hold
9/10/2020Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 9/10/2020 due to a substantial decline in the total return index and efficiency index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C+ from B- on 9/10/2020 due to a substantial decline in the total return index and efficiency index.
B
Buy
8/4/2020Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C on 8/4/2020 due to a substantial increase in the total return index, growth index and efficiency index. Operating cash flow increased 211.26% from $38.2M to $118.9M, net income increased 112.83% from $37.4M to $79.6M, and EBIT increased 108.15% from $58.9M to $122.6M.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to B- from C on 8/4/2020 due to a substantial increase in the total return index, growth index and efficiency index. Operating cash flow increased 211.26% from $38.2M to $118.9M, net income increased 112.83% from $37.4M to $79.6M, and EBIT increased 108.15% from $58.9M to $122.6M.
C
Hold
5/8/2020Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 5/8/2020 due to a major increase in the growth index, efficiency index and valuation index. Net income increased 10% from $34M to $37.4M, earnings per share increased from $0.3547 to $0.39, and total capital increased 5.96% from $1.14B to $1.21B.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 5/8/2020 due to a major increase in the growth index, efficiency index and valuation index. Net income increased 10% from $34M to $37.4M, earnings per share increased from $0.3547 to $0.39, and total capital increased 5.96% from $1.14B to $1.21B.
C
Hold
3/10/2020Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C- from C on 3/10/2020 due to a large decline in the total return index and volatility index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C- from C on 3/10/2020 due to a large decline in the total return index and volatility index.
C
Hold
2/24/2020Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 2/24/2020 due to an increase in the total return index and volatility index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 2/24/2020 due to an increase in the total return index and volatility index.
C
Hold
2/7/2020Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C- from C on 2/7/2020 due to a decline in the growth index. Earnings per share declined from $0.56 to $0.3547, and EBIT declined 5.76% from $90.1M to $84.91M.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to C- from C on 2/7/2020 due to a decline in the growth index. Earnings per share declined from $0.56 to $0.3547, and EBIT declined 5.76% from $90.1M to $84.91M.
C
Hold
1/28/2020Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 1/28/2020 due to an increase in the total return index and volatility index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C from C- on 1/28/2020 due to an increase in the total return index and volatility index.
C
Hold
11/5/2019Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 11/5/2019 due to an increase in the growth index, efficiency index and solvency index. EBIT increased 128.32% from $39.46M to $90.1M, operating cash flow increased 52.46% from $64.17M to $97.83M, and total revenue increased 20.98% from $183.58M to $222.09M.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 11/5/2019 due to an increase in the growth index, efficiency index and solvency index. EBIT increased 128.32% from $39.46M to $90.1M, operating cash flow increased 52.46% from $64.17M to $97.83M, and total revenue increased 20.98% from $183.58M to $222.09M.
D
Sell
7/31/2019Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to D+ from D on 7/31/2019 due to a significant increase in the growth index and efficiency index. EBIT increased 226.56% from $12.08M to $39.46M, operating cash flow increased 157.04% from -$112.49M to $64.17M, and net income increased 150.27% from -$102.12M to $51.34M.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to D+ from D on 7/31/2019 due to a significant increase in the growth index and efficiency index. EBIT increased 226.56% from $12.08M to $39.46M, operating cash flow increased 157.04% from -$112.49M to $64.17M, and net income increased 150.27% from -$102.12M to $51.34M.
D
Sell
2/11/2019Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D from D+ on 2/11/2019 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.52 to $0.1894, EBIT declined 59.74% from $54.32M to $21.87M, and operating cash flow declined 26.79% from $68.92M to $50.45M.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D from D+ on 2/11/2019 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.52 to $0.1894, EBIT declined 59.74% from $54.32M to $21.87M, and operating cash flow declined 26.79% from $68.92M to $50.45M.
D
Sell
12/6/2018Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C- on 12/6/2018 due to a significant decline in the total return index and volatility index.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C- on 12/6/2018 due to a significant decline in the total return index and volatility index.
C
Hold
8/2/2018Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 8/2/2018 due to a substantial increase in the growth index, total return index and efficiency index. Operating cash flow increased 153.21% from -$38.49M to $20.48M, EBIT increased 93.77% from -$29.75M to -$1.85M, and earnings per share increased from -$0.4671 to -$0.0656.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 8/2/2018 due to a substantial increase in the growth index, total return index and efficiency index. Operating cash flow increased 153.21% from -$38.49M to $20.48M, EBIT increased 93.77% from -$29.75M to -$1.85M, and earnings per share increased from -$0.4671 to -$0.0656.
D
Sell
5/2/2018Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C- on 5/2/2018 due to a substantial decline in the total return index, growth index and efficiency index. Earnings per share declined from $0.0727 to -$0.4671, net income declined 706.59% from $6.89M to -$41.82M, and EBIT declined 351.37% from $11.83M to -$29.75M.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D+ from C- on 5/2/2018 due to a substantial decline in the total return index, growth index and efficiency index. Earnings per share declined from $0.0727 to -$0.4671, net income declined 706.59% from $6.89M to -$41.82M, and EBIT declined 351.37% from $11.83M to -$29.75M.
C
Hold
1/17/2018Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 1/17/2018 due to a substantial increase in the total return index, volatility index and solvency index.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to C- from D+ on 1/17/2018 due to a substantial increase in the total return index, volatility index and solvency index.
D
Sell
11/2/2017Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to D+ from D on 11/2/2017 due to a noticeable increase in the solvency index, total return index and growth index. Total revenue increased 859.34% from $6.34M to $60.77M, EBIT increased 89.53% from -$57.27M to -$6M, and earnings per share increased from -$0.6812 to -$0.13.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to D+ from D on 11/2/2017 due to a noticeable increase in the solvency index, total return index and growth index. Total revenue increased 859.34% from $6.34M to $60.77M, EBIT increased 89.53% from -$57.27M to -$6M, and earnings per share increased from -$0.6812 to -$0.13.
D
Sell
8/4/2017Upgraded
Neurocrine Biosciences, Inc. (NBIX) was upgraded to D from D- on 8/4/2017 due to an increase in the efficiency index, growth index and volatility index. Total capital increased 185.63% from $247.14M to $705.92M, operating cash flow increased 37.64% from -$77.36M to -$48.24M, and EBIT increased 28.35% from -$79.93M to -$57.27M.
Neurocrine Biosciences, Inc. (NBIX) was upgraded to D from D- on 8/4/2017 due to an increase in the efficiency index, growth index and volatility index. Total capital increased 185.63% from $247.14M to $705.92M, operating cash flow increased 37.64% from -$77.36M to -$48.24M, and EBIT increased 28.35% from -$79.93M to -$57.27M.
D
Sell
5/10/2017Downgrade
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D- from D on 5/10/2017 due to a large decline in the total return index, efficiency index and solvency index. Net income declined 75.39% from -$44.66M to -$78.33M, total capital declined 21.51% from $314.88M to $247.14M, and the quick ratio declined from 10.11 to 10.
Neurocrine Biosciences, Inc. (NBIX) was downgraded to D- from D on 5/10/2017 due to a large decline in the total return index, efficiency index and solvency index. Net income declined 75.39% from -$44.66M to -$78.33M, total capital declined 21.51% from $314.88M to $247.14M, and the quick ratio declined from 10.11 to 10.
D
Sell
8/4/2016Downgrade
Neurocrine Biosciences Inc. (NBIX) was downgraded to D from D+ on 8/4/2016 due to a noticeable decline in the growth index, efficiency index and total return index. Net income declined 109.09% from -$19.26M to -$40.28M, earnings per share declined from -$0.2227 to -$0.4646, and EBIT declined 100.55% from -$20.86M to -$41.83M.
Neurocrine Biosciences Inc. (NBIX) was downgraded to D from D+ on 8/4/2016 due to a noticeable decline in the growth index, efficiency index and total return index. Net income declined 109.09% from -$19.26M to -$40.28M, earnings per share declined from -$0.2227 to -$0.4646, and EBIT declined 100.55% from -$20.86M to -$41.83M.
D
Sell
8/1/2016Downgrade
Neurocrine Biosciences Inc. (NBIX) was downgraded to D+ from C- on 8/1/2016 due to a decline in the total return index and valuation index.
Neurocrine Biosciences Inc. (NBIX) was downgraded to D+ from C- on 8/1/2016 due to a decline in the total return index and valuation index.
C
Hold
7/1/2016Upgraded
Neurocrine Biosciences Inc. (NBIX) was upgraded to C- from D+ on 7/1/2016 due to a large increase in the total return index, valuation index and volatility index.
Neurocrine Biosciences Inc. (NBIX) was upgraded to C- from D+ on 7/1/2016 due to a large increase in the total return index, valuation index and volatility index.
D
Sell
6/16/2016Upgraded
Neurocrine Biosciences Inc. (NBIX) was upgraded to D+ from D on 6/16/2016 due to a substantial increase in the total return index, efficiency index and growth index. Earnings per share increased from -$0.3401 to -$0.2227, net income increased 34.29% from -$29.32M to -$19.26M, and EBIT increased 32.17% from -$30.75M to -$20.86M.
Neurocrine Biosciences Inc. (NBIX) was upgraded to D+ from D on 6/16/2016 due to a substantial increase in the total return index, efficiency index and growth index. Earnings per share increased from -$0.3401 to -$0.2227, net income increased 34.29% from -$29.32M to -$19.26M, and EBIT increased 32.17% from -$30.75M to -$20.86M.
D
Sell
3/11/2016Downgrade
Neurocrine Biosciences Inc. (NBIX) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 5.03% from $446.94M to $424.45M.
Neurocrine Biosciences Inc. (NBIX) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 5.03% from $446.94M to $424.45M.
D
Sell
9/29/2015Downgrade
Neurocrine Biosciences Inc. (NBIX) was downgraded to D+ from C- on 9/29/2015 due to a noticeable decline in the total return index and volatility index.
Neurocrine Biosciences Inc. (NBIX) was downgraded to D+ from C- on 9/29/2015 due to a noticeable decline in the total return index and volatility index.
C
Hold
9/10/2015Upgraded
Neurocrine Biosciences Inc. (NBIX) was upgraded to C- from D+ on 9/10/2015 due to a noticeable increase in the total return index and volatility index.
Neurocrine Biosciences Inc. (NBIX) was upgraded to C- from D+ on 9/10/2015 due to a noticeable increase in the total return index and volatility index.
D
Sell
8/26/2015Downgrade
Neurocrine Biosciences Inc. (NBIX) was downgraded to D+ from C- on 8/26/2015 due to a noticeable decline in the total return index.
Neurocrine Biosciences Inc. (NBIX) was downgraded to D+ from C- on 8/26/2015 due to a noticeable decline in the total return index.
C
Hold
7/30/2015Downgrade
Neurocrine Biosciences Inc. (NBIX) was downgraded to C- from C on 7/30/2015 due to a large decline in the growth index, efficiency index and total return index. Operating cash flow declined 176.78% from -$18.18M to $13.96M, and total capital declined 3.67% from $484.73M to $466.94M.
Neurocrine Biosciences Inc. (NBIX) was downgraded to C- from C on 7/30/2015 due to a large decline in the growth index, efficiency index and total return index. Operating cash flow declined 176.78% from -$18.18M to $13.96M, and total capital declined 3.67% from $484.73M to $466.94M.
C
Hold
5/1/2015Upgraded
Neurocrine Biosciences Inc. (NBIX) was upgraded to C from D+ on 5/1/2015 due to a significant increase in the total return index, growth index and volatility index. Operating cash flow increased 18.77% from -$15.31M to -$18.18M.
Neurocrine Biosciences Inc. (NBIX) was upgraded to C from D+ on 5/1/2015 due to a significant increase in the total return index, growth index and volatility index. Operating cash flow increased 18.77% from -$15.31M to -$18.18M.
D
Sell
6/4/2014Downgrade
Neurocrine Biosciences Inc. (NBIX) was downgraded to D+ from C- on 6/4/2014 due to a noticeable decline in the total return index, efficiency index and growth index. Operating cash flow declined 10.22% from -$10.88M to -$9.77M.
Neurocrine Biosciences Inc. (NBIX) was downgraded to D+ from C- on 6/4/2014 due to a noticeable decline in the total return index, efficiency index and growth index. Operating cash flow declined 10.22% from -$10.88M to -$9.77M.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
